Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet
Psyence Biomed Announces $2.0 Million Private Placement
Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant in a private placement.
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial
A leading clinical trial site management organization (SMO), Australian Clinical Trial Network (ACTioN), has been engaged to implement patient recruitment and retention strategies
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
Psyence Biomed obtains exclusive worldwide supply rights to Optimi’s GMP-certified, nature-derived psilocybin for its drug development and commercialization initiatives in Palliative Care
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress
Psyence Biomed today announced the favorable outcome of the Nasdaq Listing Qualifications Hearing that was held on October 31st, 2024. The Nasdaq Hearings Panel has granted Psyence Biomed an extension until December 31st, 2024, to demonstrate compliance with all Nasdaq continued listing rules.
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
Psyence Biomed today announced the favorable outcome of the Nasdaq Listing Qualifications Hearing that was held on October 31st, 2024. The Nasdaq Hearings Panel has granted Psyence Biomed an extension until December 31st, 2024, to demonstrate compliance with all Nasdaq continued listing rules.
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions - Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions - Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions - Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
PsyLabs to exclusively supply Psyence Biomed with high purity, pharmaceutical grade psilocybin for its second development indication, Alcohol Use Disorder, as previously announced